XERS Q3 2025 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M+37.1% YoY

Gross Profit

$63M85.2% margin

Operating Income

$7M9.0% margin

Net Income

$621,0000.8% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$18M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$370M

Total Liabilities

$371M

Stockholders' Equity

-$861,000

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$54M	+37.1%
Gross Profit	$63M	$41M	+55.8%
Operating Income	$7M	-$13M	+152.2%
Net Income	$621,000	-$16M	+103.9%

Revenue Segments

Product

$74M86%

Keveyis

$12M14%